March 28, 2025 06:53 AM EDT

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Ayisha Sharma

News Reporter

Merck KGaA is spending $85 million to tap global commercialization rights to pimicotinib, a candidate for non-malignant tumors that it licensed from China’s Abbisko Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Vertex’s second-generation diabetes cell therapy fails early-stage study

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug

Ayisha Sharma

News Reporter

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Vertex’s second-generation diabetes cell therapy fails early-stage study

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic